Development of an immune-armed therapeutic adenoviral platform for pediatric brain tumors
The POPCORN project aims to develop an innovative oncolytic virus platform that enhances anti-tumor immune responses for treating aggressive pediatric brain tumors, improving survival rates and quality of life.
Projectdetails
Introduction
Diffuse Midline Gliomas (DMGs) are the most aggressive pediatric brain tumors in desperate need of curative treatment. The median life expectancy of these children remains below 14 months after diagnosis, and nearly none survive beyond the second year.
Challenges in Treatment
Similarly, for other high-risk pediatric brain tumors, there is hardly any option after recurrence, and long-term survivors are faced with life-long sequelae that impact their quality of life. In this scenario, there is an urgent need for innovative, efficacious, and safe therapies for these patients.
Oncolytic Viruses as a Solution
Oncolytic viruses are promising anticancer biotherapeutic agents that offer a unique combination of safety profile, direct antineoplastic activity, and the induction of anti-tumor immune responses. Recently, a Phase I clinical trial showed that combining the oncolytic adenovirus Delta-24-RGD and radiotherapy is non-toxic and results in anti-tumor responses and prolonged median overall survival (17.8 months) in patients.
Limitations of Current Approaches
However, results are still insufficient to be curative due to counteracting mechanisms intrinsic to the tumor microenvironment and also triggered by the virus that eventually exceeds its immunostimulatory properties.
Proposed Technology: POPCORN
The proposed technology, termed “POPCORN,” is an oncolytic-based platform capable of expressing immunomodulatory single-domain antibodies directed to intrinsic targets in these tumors.
Development Plan
We will develop the POPCORN Proof of Concept using a state-of-the-art experimental approach and validate its safety and efficacy in vitro and relevant in vivo DMG models.
IND-Enabling Studies
We will also perform IND-enabling studies and apply for PUMA/PRIME designation.
Intellectual Property and Commercialization
Additionally, we will work on the IPR strategy, and a value proposition to develop and commercialize the POPCORN platform will be generated.
Vision for the Future
We envision the POPCORN platform becoming a game changer in treating DMGs, providing a one-of-a-kind tool for eliminating these aggressive tumors that could be extensive to other difficult-to-treat pediatric brain tumors.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 150.000 |
Totale projectbegroting | € 150.000 |
Tijdlijn
Startdatum | 1-5-2025 |
Einddatum | 31-10-2026 |
Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- UNIVERSIDAD DE NAVARRApenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
MANUNKIND: Determinants and Dynamics of Collaborative ExploitationThis project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery. | ERC STG | € 1.497.749 | 2022 | Details |
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressureThe UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance. | ERC STG | € 1.498.280 | 2022 | Details |
Uncovering the mechanisms of action of an antiviral bacteriumThis project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function. | ERC STG | € 1.500.000 | 2023 | Details |
The Ethics of Loneliness and SociabilityThis project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field. | ERC STG | € 1.025.860 | 2023 | Details |
MANUNKIND: Determinants and Dynamics of Collaborative Exploitation
This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure
The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.
Uncovering the mechanisms of action of an antiviral bacterium
This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.
The Ethics of Loneliness and Sociability
This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Multimodal “4D”-therapy of pediatric high grade gliomaThis project aims to develop a novel multimodal treatment strategy for pediatric high-grade glioma by combining targeted therapies, gene therapy, and CAR-T cells to improve patient outcomes. | ERC STG | € 1.493.711 | 2024 | Details |
Leveraging Polymer Therapeutics as Nanomedicine for Local Glioblastoma ImmunotherapyGLIOMERS aims to develop a brain-penetrating polymeric drug delivery system to enhance immunotherapy efficacy for glioblastoma by localizing treatment and stimulating antitumor immunity. | ERC STG | € 1.498.175 | 2025 | Details |
A disruptive hypoxia activated prodrug for the treatment of resistant cancers: an AI-driven approachTUMAGOSTIC aims to advance CP-506, a targeted Hypoxia Activated Prodrug, through clinical trials to improve cancer treatment efficacy and patient outcomes, with commercialization potential exceeding €450M. | EIC Accelerator | € 2.462.533 | 2024 | Details |
Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkankerAdjuTec-Therapeutics ontwikkelt een gepersonaliseerde immunotherapie, PanCaVax, voor alvleesklierkanker om de overlevingskansen van patiënten na operatie te verbeteren en streeft naar OD-status voor versnelde registratie. | MIT Haalbaarheid | € 20.000 | 2020 | Details |
Multimodal “4D”-therapy of pediatric high grade glioma
This project aims to develop a novel multimodal treatment strategy for pediatric high-grade glioma by combining targeted therapies, gene therapy, and CAR-T cells to improve patient outcomes.
Leveraging Polymer Therapeutics as Nanomedicine for Local Glioblastoma Immunotherapy
GLIOMERS aims to develop a brain-penetrating polymeric drug delivery system to enhance immunotherapy efficacy for glioblastoma by localizing treatment and stimulating antitumor immunity.
A disruptive hypoxia activated prodrug for the treatment of resistant cancers: an AI-driven approach
TUMAGOSTIC aims to advance CP-506, a targeted Hypoxia Activated Prodrug, through clinical trials to improve cancer treatment efficacy and patient outcomes, with commercialization potential exceeding €450M.
Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkanker
AdjuTec-Therapeutics ontwikkelt een gepersonaliseerde immunotherapie, PanCaVax, voor alvleesklierkanker om de overlevingskansen van patiënten na operatie te verbeteren en streeft naar OD-status voor versnelde registratie.